Horizon Pharma shares offer 'significant value,' says Stifel Stifel sees "significant value" in shares of Horizon Pharma with today's pullback and it keeps a Buy rating on the name. The firm says Express Scripts and Caremark putting Duexis and Vimovo on their exclusion lists is a "large disappointment," but it believes management has several avenues to offset the impact. Stifel lowered its price target for shares to $20 from $25.
Horizon Pharma files to sell 11.66M shares for existing holders Horizon Pharma announced a proposed underwritten secondary offering of 11.66M of its ordinary shares held by certain of its existing shareholders. Morgan Stanley, Citigroup, Cowen and Jefferies are acting as joint book-running managers for this offering. JMP Securities is acting as financial advisor for this offering.